3 reports

The study conducted in Japan consisted of randomized, double-blind, placebo-controlled Phase III clinical trials in patients with rheumatoid arthritis with disease-modifying anti-rheumatic drugs (DMARDs).

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • Tuberculosis
  • Daiichi Sankyo Company

The purpose of the study is to assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are tolerant to or have had an inadequate response to non steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs DMARDs and/ or TNF

  • Cancer
  • Targeted Therapy
  • Therapy
  • Tuberculosis
  • Novartis AG

Research and Development Brief The drug candidate has also been demonstrated in animal models of rheumatoid arthritis (RA), CDK## inhibitors lead to profound reduction of cellular infiltration into arthritis joints, suggesting a disease-modifying anti-rheumatic activity.

  • Blood Disease
  • Therapy
  • Tuberculosis
  • United States
  • AstraZeneca PLC